Chronic kidney disease in cats requiring ongoing subcutaneous fluid therapy

Feline CKD is one of the best-studied chronic conditions in small-animal veterinary medicine, but almost none of that literature is US-specific, population-level, or about the practice this domain actually turns on: an owner, at home, giving a needle-stick subcutaneous fluid bolus to their own cat, repeatedly, for years. That practice — not a marketed product — is the incumbent this domain exists to hold context on, and it has exactly one strong, US-majority, primary-source survey behind it (§5, [1]). Everything else in this file is either a smaller or non-US epidemiology comparator, a human-medicine analog (implanted vascular access ports, §5) offered because no comparable literature exists for the veterinary-specific implanted alternative, or a section that came back thin and says so. Read the thinness up front, the same instruction this repo gives every dossier: no connector in this repository reaches veterinary population, pricing, or payer data at all (the same structural fact idea-007's own Claims section already establishes independently for reimbursement and TAM), so every quantity below that is not a PubMed record or an openFDA record was retrieved by following a web search to the primary document it pointed at — and several of those attempts (ISFM full text via SAGE and ResearchGate, AAHA's fluid therapy FAQ, three separate vendor pages for the one named marketed device) returned 403s, 404s, or unreadable content and are recorded as not retrieved, not papered over as silent.

This file carries no confidence tags. Every line below is context with a source attached. To affect a score, a line must be copied into a candidate's ## Claims as unverified via engine/scripts/append_research_claims.py and pass the Verifier or Corroborator.

1. Condition & epidemiology

as_of: 2026-08-27 · sources searched: PubMed via connectors literature / literature-detail (queries: "feline chronic kidney disease prevalence United States", "chronic kidney disease cats prevalence general practice", "chronic kidney disease prevalence cats veterinary teaching hospital United States", "senior cat prevalence azotemia geriatric screening", "risk factors development chronic kidney disease cats primary care veterinary hospitals", "VetCompass chronic kidney disease cats prevalence", "Marino prevalence classification chronic kidney disease cats age groups"), plus WebSearch for a US-specific aggregate figure · not searched: AVMA member surveys, Banfield/Mars "State of Pet Health" reports (no connector reaches them, and this dossier did not repeat the diabetes dossier's exhaustive multi-query attempt at these specifically — a gap, not a settled negative, unlike the diabetes dossier's §1)

Verbatim, for anything load-bearing:

"We found significant concurrence between CKD and DJD in cats of all ages... The prevalence of CKD in the RS and DJD groups was higher than expected at 50% and 68.8%, respectively." — [2] (abstract, retrieved via literature-detail)

"From 353,448 cats attending 244 clinics, the prevalence of CKD was estimated as 1.2 per cent (95 per cent CI 1.1 per cent to 1.3 per cent)." — [3]

"Diagnostic testing revealed a high prevalence of previously unrecognized disease, including chronic kidney disease (49 of 80 [61.3%])..." — [5]

Gaps: [2] is described in secondary web sources as drawn from a US feline-only practice, but the abstract text retrieved here does not itself state a country, so that attribution is recorded with that caveat rather than as a confirmed fact. No source establishes a current, general-population, US-specific prevalence figure with a defined denominator — [2] is a single-practice cohort, [3] is UK, [5] is a small (n=80 tested), self-selected "wellness" cohort at one US teaching hospital, and [4] is a case-control study whose case:control ratio is fixed by design and cannot yield a prevalence estimate. This is the same shape of gap the veterinary-diabetes dossier records for its own domain (dated/local figures standing in for a population estimate), and it is the direct ancestor of idea-007's own TAM claim 8, which market returned unverifiable for exactly this reason. Not searched further this pass: Banfield/Mars aggregated EHR reports, which might close this gap if reachable.

2. Care pathway & clinical setting

as_of: 2026-08-27

Two clearly different settings appear in the sources retrieved, and the direction of travel between them is itself the domain's central fact: subcutaneous fluid therapy for feline CKD has moved from something done to a cat in a clinic to something owners are taught to do at home, and that transition — not a novel indication — is what a large majority of the CKD population now experiences.

Gaps: No source retrieved establishes the general-practice-vs-referral split for who places an implant (this candidate's mechanism) — because no such implant is standard of care; the two implanted-device analogs found (subcutaneous fluid port / "GIF Tube," §5, and the SUB device, §5) are both surgically placed, but no source states what fraction of that placement happens in general practice versus specialty/soft-tissue-surgery referral. This is a direct twin of idea-007's own deck-surfaced assumption ("General-practice veterinarians, not only referral surgeons, will place a subcutaneous fluid port as a minor procedure," claim recorded in idea-007 as unverified) and it remains open here as well. Visit frequency and staffing/throughput implications of either pathway step are likewise not established by any source retrieved.

3. User groups & incentives

as_of: 2026-08-27

Gaps: No source separates veterinary-technician incentives (who often does the actual in-clinic teaching) from veterinarian incentives. No source addresses clinic-side economics of supplying fluids/giving sets (markup vs near-cost). No source measures the purchaser role in dollar terms for the veterinary channel specifically — this is the same shape of gap the diabetes dossier records for its own domain.

4. Standard of care & clinical evidence

as_of: 2026-08-27 · sources searched: PubMed via literature/literature-detail for the ISFM guideline record and abstract; direct WebFetch attempts at the guideline's full text (SAGE and ResearchGate) and at IRIS's own guideline pages · not searched: AAHA's 2024 Fluid Therapy Guidelines full text (aaha.org returned HTTP 403 to a direct fetch, the same class of failure this repo's other dossiers already name for fda.gov and aaha.org)

Gaps: This is the section most exposed to the title-vs-conclusion trap this repo's own backlog names (docs/backlog.md 0.2) — a secondary source's paraphrase of the guideline reads as authoritative and this dossier deliberately declines to treat it as a finding because the primary document was never successfully retrieved. Anyone re-running this should try IRIS's own current PDF (iris-kidney.com's guideline landing page loaded successfully and confirms an "IRIS Treatment Recommendations for Cats (2026)" document exists, but the specific PDF URL guessed here 404'd) or a library-mediated fetch of the SAGE full text.

5. Reference products — and why people stop using them

as_of: 2026-08-27 · sources searched: PubMed via literature/literature-detail (queries listed in §10), connectors classification --device-name "vascular access port", connectors recalls --product-code PXK, connectors clearances --product-code PXK, plus WebSearch/WebFetch for the named veterinary product · not searched: MAUDE (no connector in this repo, docs/backlog.md 1.9); any veterinary-specific recall channel (none exists, per idea-007's own claim 15)

This domain has three things worth separate abandonment records, not the usual two: the practice being displaced (needle-and-bag home fluid administration), the veterinary implanted alternative that already exists in a small way (subcutaneous fluid ports, marketed at least as the "GIF Tube"), and the closest predicate/analog class for the candidate's own mechanism risk — human implanted vascular access ports, whose infection and complication literature is the best-quantified thing in this entire dossier.

Needle-and-bag home subcutaneous fluid administration (the incumbent practice)

• What it is: repeated (often daily to several-times-weekly) subcutaneous boluses of isotonic crystalloid fluid, delivered via a needle connected to a hanging fluid bag and giving set, performed by the owner at home after in-clinic training.
• Price / what it realizes per unit: not established from a primary source; several consumer-health/veterinary-marketing pages quote per-treatment or per-month figures, but none is a primary billing study or fee schedule and none is recorded here as a finding (§6 explains why).
• Evidence behind it: §4 — a guideline-endorsed but, per the guideline's own general self-description, thinly trial-evidenced practice.
• Adoption: the default, near-universal standard of care for maintaining hydration in CKD cats once fluid therapy is indicated; not quantified as an installed base because it is a practice, not a product.
• **Abandonment record — why people stop, and the closest thing to a demand-evidence table this repo has for this candidate:**

• Verbatim:

"399 (85%) said they gave SC fluids, whereas 57 (12%) did not and 12 (3%) stated that they tried but could not." — [1] (full text via PMC mirror)

"155 (39%) owners stated they have skipped fluid administration in the past 2-4 weeks owing to their cats being frustrated." — [1]

"13 (23%) never discussed it with their veterinarian, 19 (33%) stated their veterinarian said it was not needed at the time, five (9%) said it was not tolerated and two (4%) said that they were not comfortable with the procedure." — [1]

Read this the way the potassium and veterinary-diabetes dossiers read their own equivalent sections. This is real, retrieved, revealed-behaviour evidence that a meaningful minority of the population never starts, cannot sustain, or routinely skips the needle-based incumbent, and for stated reasons that map directly onto what an implanted, metered alternative claims to fix (needle aversion, tolerance, time). It is not evidence that owners would adopt this specific unbuilt candidate. The revealed-behaviour twin answers "what did people already do about the incumbent's burden," which is answerable; it does not answer "would they choose this implant," which is the class-3 question idea-007's own Claims section (claim 16) already correctly declines to answer via the adoption connector. Geographic note: 352 of 468 respondents (75%) were US-based, with the UK, Australia and Canada making up most of the remainder — a US-majority but not US-exclusive sample, recorded with that caveat rather than treated as a clean US figure.

Subcutaneous fluid ports already marketed in feline practice ("GIF Tube" and generic

equivalents — idea-007's own named predicate/analog)

• What it is: a surgically implanted, fenestrated silicone tube placed subcutaneously with an externalized or subcutaneous access point, marketed (per a named commercial product found by search, "GIF Tube," manufacturer Practivet) as a needleless alternative to daily injections. Existence in real clinical use is confirmed by a primary source: the case report at [7] describes a cat managed for approximately five years with "a previously placed and subsequently removed GIF tube."
• Price / what it realizes per unit: not found. Three separate attempts to retrieve a primary vendor page failed outright — practivet.com/gif-tube returned HTTP 404; a MarVista Vet client brochure PDF was fetched but returned unreadable/garbled binary content; a Patterson Veterinary product page loaded but did not contain the product listing searched for. A WebSearch-only synthesis named "silicone" as the material and "Practivet" as the manufacturer, but per this repo's sourcing rule a search result is not a source of record, so those two facts are recorded here as seen, not used rather than as dossier content independent of what [7]'s primary text itself establishes (which is the product name and its real-world use, not its material or price).
• Evidence behind it: no accuracy, complication-rate, or outcome literature beyond the single case report at [7] was found for this specific product.
• Adoption: not established at a population level — the same conclusion idea-007's own claim 3 already reaches independently via the adoption connector (unverifiable).
• Abandonment record — why people stop:

• Verbatim:

"...a non-healing ulcerated mass at the site of a previously placed and subsequently removed GIF tube" — [7] (case narrative, PMC mirror)

Note the site, and note it is exactly the design lever idea-007's own frontmatter names: the sarcoma in [7] developed at the interscapular injection site — the traditional placement this candidate's intended_use: deliberately excludes in favor of a defined, resectable, non-interscapular location. This is n=1, no denominator, no incidence figure, and appraises nothing about the candidate's own design premise; it is recorded here, as idea-007's own claim 4 already records it, as a lead consistent with the design rationale and nothing stronger.

Human implanted vascular access ports — the closest quantified predicate/analog class

for infection and inflammation risk

Because no veterinary implanted-port literature reaches cohort scale, the human analog is the only place in this domain where a real, denominator-based infection/complication rate exists. It is a different species, different indication (IV drug/nutrition delivery, not SC hydration), and a different regulatory class (Class II, 510(k), product code PXK, regulation 880.5965, confirmed via connectors classification), so it is offered here as the closest available quantification of "what happens when you leave an implanted access port under skin for a long time," not as veterinary evidence.

• What it is: a totally implantable venous access port (chest port, arm port) accessed percutaneously through a self-sealing septum, used for long-term IV therapy in oncology, home parenteral nutrition, and similar indications.
• Regulatory status (US): Class II, 510(k) pathway, product code PXK ("Vascular Access Port Kit") — verified via `connectors classification --device-name "vascular access port". **Notably, a direct query of both connectors recalls --product-code PXK` and connectors clearances --product-code PXK over a 25-year window (2001-08-29 to 2026-08-27) returned zero records in both.** This is recorded as a genuine "none found under this exact code," not as "no implanted vascular access port has ever been cleared or recalled" — the device family is old and may be cleared or tracked predominantly under other/legacy product codes not captured by this single lookup.
• **Evidence behind it — infection/complication rates, the load-bearing quantities in this entire dossier:**

• Verbatim:

"The incidence of catheter-related bloodstream infection was 0.05/1000 catheter days and the incidence of pocket/tunnel infection was 0.39/1000 catheter days." — [11]

"A total of 20 patients (1.2%) had early port infections; 15 patients (0.9%) had positive blood cultures... The port-related 30-day mortality rate was 0.2% (4 of 1,714 patients)." — [12]

Read this in both directions, deliberately. These are low absolute rates for a well-established, decades-old human device class in a population that is mostly not comparable to an elderly CKD cat (different comorbidity profile, different implant duration intent, different species dermal/immune biology). They establish that chronic subcutaneous port access can be operated at a low measured infection rate in the closest available analog population — they do not establish that a feline implant would achieve anything like this rate, and they say nothing about the oncologic (sarcoma) risk that is this candidate's own file's stated central hazard (idea-007 claim 13), which has no analog in the human vascular-access literature at all.

Gaps, across all three sub-sections: No veterinary-specific cohort complication study exists for any implanted feline SC access device (fluid port or otherwise) at a scale comparable to the human vascular-access literature or even to the SUB device literature in §7/§8. MAUDE narratives are unreachable (no connector). A systematic complication rate for home needle-based SC fluid administration specifically (not just discontinuation/skip behaviour) was searched for and not found.

6. Reimbursement landscape

as_of: 2026-08-27

Structural, not merely thin, and consistent with idea-007's own independently-verified finding. Idea-007's claim 1/2 chain already establishes via the regulation connector (21 CFR 807.65(b)) that veterinary-only device manufacturers sit outside the same federal apparatus (registration/listing) that generates HCPCS/CPT/coverage activity in the human system; hcpcs, payment, coverage, and procedures in this repo query exclusively CMS/human-payer systems and have no veterinary jurisdiction to query. That structural fact, not a search failure, is why this section is thin.

What was searched and what came back, distinguished rather than collapsed: a WebSearch for pet-insurance coverage of CKD treatment, including subcutaneous fluids, surfaced several insurer marketing pages (Healthy Paws, MetLife) stating in general terms that CKD treatment including "sub-Q fluids" is covered at typical reimbursement percentages once a policy is active and the condition is not pre-existing, and several consumer-cost-estimate sites (wagwalking, vetreceipt, vetlens, spectrumcare) quoting per-treatment and per-month dollar figures. None of these is recorded as dossier content. They are marketing pages and cost-estimate content sites without a disclosed, dated, primary policy document or billing methodology — exactly the "a search result is never a source of record" case this repo's sourcing rule excludes, the same treatment the veterinary-diabetes dossier gives equivalent consumer-health content. They are named here so a later reader knows they were seen and deliberately not used, not treated as an oversight. No primary insurer policy document, and no NAPHIA-style aggregate industry report, was fetched in this pass.

Gaps: commercial pet-insurance coverage-policy documents specifically naming subcutaneous fluid therapy or implanted device coverage — genuinely open, not reachable by any connector here, and not resolved by the marketing pages found. A systematic cash-price survey for either needle-based supplies or any implanted port kit was searched for (§5) and not found.

7. Technology trajectory

as_of: 2026-08-27

Verbatim:

"Kinks were reported in 11 of 71 SUB 2.0s (15.5%) and 0 of 50 SUB 3.0s (0%)... Survival rates to 90 days were 75%, 85%, and 94% in groups 1, 2, and 3, respectively." — [10]

"Overall, post-operative complications occurred in 9/30 (30%) patients... Owner satisfaction was very good in 28/30 (93.3%) cases." — [8]

Gaps: No patent-landscape check was possible — this mirrors idea-007's own claim 11/FTO gap exactly (PATENTSVIEW_API_KEY unset in this environment); low-fouling/antifouling implant-surface-chemistry literature specific to a subcutaneous fluid-delivery application was searched for once (§10) and returned no relevant record, a genuine "not found" rather than "not searched." No founding-technology citation for implanted vascular access ports generally (the human-analog equivalent of the diabetes dossier's Clark & Lyons 1962 citation) was located in the time available for this pass — attempted once, not found, and not pursued further.

8. Market players & dynamics

as_of: 2026-08-27 · sources searched: company/product web pages followed from search results, three of which failed to return usable content and are named as such rather than silently dropped

Gaps: No funding, revenue, or market-size figure for any player above was located or used — no market-research-firm report was even encountered in this pass (unlike the diabetes dossier, which found and deliberately excluded several). Whether other veterinary-specific SC fluid port products exist beyond Practivet's was not exhaustively searched; only the product named in idea-007's own frontmatter and confirmed by a case report was pursued.

9. Open questions — and what would settle them

Class-3 questions are recorded here and never answered here. Both class-3 rows above have a revealed-behaviour twin recorded in §5, per docs/research-lane-spec.md §3.1.

10. Provenance & staleness

What this dossier has never looked at: MAUDE narratives (no connector exists in this repo, docs/backlog.md 1.9); any veterinary trade-source catalogue (Covetrus, Patterson Vet's full catalogue, MWI) for pricing on either needle-based supplies or an implanted port kit; AVMA member surveys or Banfield/Mars aggregated-EHR reports for a US-specific CKD prevalence figure; the full text of the ISFM/IRIS guideline (blocked twice on this pass, not silent — a different gap than "guideline is silent on this"); a systematic complication-rate study for home needle-based SC fluid administration (searched for, not found — may genuinely not exist in the published literature); any veterinary-specific recall or adverse-event channel (none exists, per idea-007's own claim 15's independent finding); a founding-history citation for implanted vascular access ports as a device class (attempted once, not found). Absence of scanning is not absence of change, and a later reader should treat §2, §3, and the reimbursement half of §6 as a starting point, not coverage.

Sources

Numbered by first use in the sections above. Full resolvable identifiers, no confidence tags.

1. Cooley CM, Quimby JM, Caney SM, Sieberg LG. "Survey of owner subcutaneous fluid practices in cats with chronic kidney disease." J Feline Med Surg. 2018;20(10):884-890. PMID
   1. Full text read via PMC mirror: https://pmc.ncbi.nlm.nih.gov/articles/PMC11129241/
2. Marino CL, et al. "Prevalence and classification of chronic kidney disease in cats randomly selected from four age groups and in cats recruited for degenerative joint disease studies." J Feline Med Surg. 2014. PMID 24217707 (abstract retrieved via connectors literature-detail).
3. O'Neill DG, et al. "Chronic kidney disease in cats attending primary care practice in the UK: a VetCompass study." Vet Rec. 2019. PMID 31023949 (abstract retrieved via connectors literature-detail).
4. "Risk factors associated with the development of chronic kidney disease in cats evaluated at primary care veterinary hospitals." J Am Vet Med Assoc. 2014. PMID 24432964 (abstract retrieved via connectors literature-detail).
5. "Clinically important abnormalities are common in senior cats perceived to be healthy by owners." J Am Vet Med Assoc. 2026. PMID 42526494 (abstract retrieved via `connectors literature-detail`).
6. Sparkes AH, et al. "ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease." J Feline Med Surg. 2016. PMID 26936494 (abstract retrieved via connectors literature-detail; full text attempted at https://journals.sagepub.com/doi/full/10.1177/1098612x16631234 (HTTP 403, 2026-08-27) and https://www.researchgate.net/publication/296689616 (HTTP 403, 2026-08-27) — neither retrieved).
7. McLeland SM, Imhoff DJ, Thomas M, Powers BE, Quimby JM. "Subcutaneous fluid port-associated soft tissue sarcoma in a cat." J Feline Med Surg. 2013. PMID 23413270 = PMC11383148 (identity confirmed directly by fetching https://pmc.ncbi.nlm.nih.gov/articles/PMC11383148/, 2026-08-27; full text read there).
8. "Management of chronic pleural effusion in dogs and cats using the PleuralPort device: complications and outcome of 30 cases (2005-2024)." N Z Vet J. 2025. PMID 39956534 (abstract retrieved via connectors literature-detail).
9. "Long-Term Outcomes After Prophylactic Infusion of 2% Tetrasodium Ethylenediaminetetraacetic Acid in 95 Subcutaneous Ureteral Bypass Devices in 66 Cats With Benign Ureteral Obstructions." J Vet Intern Med. 2025. PMID 40011049 (abstract retrieved via `connectors literature-detail`).
10. "The Subcutaneous Ureteral Bypass 3.0 device shows improved short-term outcomes compared to the 2.0 device for treatment of benign ureteral obstructions in cats." Am J Vet Res.
    1. PMID 40054427 (abstract retrieved via connectors literature-detail).
11. "A prospective observational study on 249 subcutaneous central vein access ports in a Swedish county hospital." Acta Oncol. 2013. PMID 23432403 (abstract retrieved via connectors literature-detail).
12. "Risk Factors for Early Port Infections in Adult Oncologic Patients." *J Vasc Interv Radiol.* 2020. PMID 32792279 (abstract retrieved via connectors literature-detail).
13. "Totally implantable venous access ports: A systematic review and meta-analysis comparing subclavian and internal jugular vein punctures." Phlebology. 2022. PMID 35200052 (abstract retrieved via connectors literature-detail).
14. "Owners' experiences of caring for cats with chronic kidney disease in the UK." *J Feline Med Surg.* 2025. PMID 40235283 (abstract retrieved via `connectors literature-detail`).
15. "Clinical management of feline chronic kidney disease in Portugal: a questionnaire-based study." J Feline Med Surg. 2023. PMID 37987623 (abstract retrieved via connectors literature-detail).
16. openFDA device/classification, product_code=PXK ("Vascular Access Port Kit," regulation 880.5965, review panel HO). Retrieved via `python3 -m connectors classification --device-name "vascular access port"`, 2026-08-27.
17. openFDA device/recall and device/510k, product_code=PXK, window 2001-08-29 to 2026-08-27. Retrieved via python3 -m connectors recalls --product-code PXK --since 25y and python3 -m connectors clearances --product-code PXK --since 25y, 2026-08-27 — zero records returned by both.
18. IRIS (International Renal Interest Society) guideline listing page, https://www.iris-kidney.com/iris-guidelines-1 (fetched successfully 2026-08-27; confirms an "IRIS Treatment Recommendations for Cats (2026)" document exists as a named guideline, but the specific PDF was not located at the URL guessed: https://www.iris-kidney.com/pdf/IRIS_Treatment_Recommendations_2023-Cats.pdf, HTTP 404, 2026-08-27).
19. Practivet, "GIF Tube" product page, https://www.practivet.com/gif-tube — attempted 2026-08-27, HTTP 404, not retrieved.
20. MarVista Veterinary Associates, GIF Tube client brochure PDF, https://www.marvistavet.com/sites/site-5348/documents/gifclientbrochure.pdf — fetched 2026-08-27 but returned unreadable/garbled binary content, not usable, not used.
21. Patterson Veterinary Supply, product family page, https://www.pattersonvet.com/Supplies/ProductFamilyDetails/PF_400542 — fetched 2026-08-27; page loaded but did not contain the product listing sought, not used.
22. Norfolk Vet Products, SUB 3.0 product page, https://norfolkvetproducts.com/products/sub-3/ — fetched 2026-08-27, returned blank content, not retrieved.
23. AAHA, "2024 AAHA Fluid Therapy Guidelines for Dogs and Cats — Frequently Asked Questions," https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/fluid-therapy-frequently-asked-questions/ — attempted 2026-08-27, HTTP 403, not retrieved.
24. WebSearch results (not primary documents; named per this repo's sourcing rule as seen and deliberately not used as dossier content) citing Healthy Paws Pet Insurance (healthypawspetinsurance.com), MetLife Pet Insurance (metlifepetinsurance.com), and consumer cost-estimate sites wagwalking.com, vetreceipt.com, vetlens.com, and spectrumcare.pet, regarding pet-insurance coverage of CKD treatment and cash cost of subcutaneous fluid therapy — no primary policy document or billing methodology was fetched or cited from any of these.